Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose caffeine in premature infants
IRCT20240929063207N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of caffeine in apnea of prematurity (AOP), bronchopulmonary dysplasia (BPD) and respiratory distress syndrome (RDS) (2 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Started Jan 2025; status: completed.
02
Drugs
caffeine
03
Conditions
apnea of prematurity (AOP)bronchopulmonary dysplasia (BPD)respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20240929063207N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240929063207N1.